Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project; SKION LATER Q2008 research: Is pulmonary dysfunction a late effect of cyclophosphamide treatment?

Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project; SKION LATER Q2008 research: Is pulmonary dysfunction a late effect of cyclophosphamide treatment? - SKION LATER Q2008 - pulmonology

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47559

Enrollment

520

Registered

2015-01-23

Start date

2016-05-04

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary dysfunction

Interventions

None listed

Eligibility

Age

12 Years to 99 Years

Inclusion criteria

Inclusion criteria: childhood cancer survivors (CCS) who either received cyclophosphamide (Cy) treatment but no other potentially pulmotoxic treatment or who received neither Cy nor any other potentially pulmotoxic treatment

Exclusion criteria

Exclusion criteria: childhood cancer survivors who received potentially pulmotoxic treatment

Design outcomes

Primary

Measure	Time frame
Abnormal PFT, defined as TLC/FVC	—

Countries

Netherlands

Outcome results